China
Africa
Explore chapters and articles related to this topic
Intravenous Immunoglobulins
Published in Stanley R. Resor, Henn Kutt, The Medical Treatment of Epilepsy, 2020
K. Van Rijckevorsel-Harmant, M. Delire
The use of IVIG has been associated acutely with fever, headache, and skin rash. Usually these adverse effects respond to symptomatic treatment. If IVIG is infused too quickly, hypotension may develop. The long-term adverse effects are unknown, and the viral safety of IVIG preparations is an important concern (12,13). Considering these uncertainties, it is prudent to consider IVIG when other treatments have failed or when there are contraindications for using ACTH and corticosteroids in severe infantile epilepsies.
Measles and its neurological complications
Published in Avindra Nath, Joseph R. Berger, Clinical Neurovirology, 2020
Benedikt Weissbrich, Jürgen Schneider-Schaulies
Currently, there is no specific antiviral therapy for measles. Symptomatic treatment depends on the clinical manifestations and may include antipyretics and cough suppressants. Antibiotics are indicated when there is bacterial superinfection.
The professional sector
Published in Miho Ushiyama, Incorporating Patient Knowledge in Japan and the UK, 2019
As discussed in more detail later, standard treatment and steroid withdrawal treatment differ in their goals. Steroid withdrawal treatment can actually induce severe rebounds in having patients discontinue steroid medication. Standard treatment, on the other hand, aims to avoid such exacerbations and to preserve a state as close to symptomless as possible, and drug therapy centred around steroids is at the core of this treatment. The guidelines contain the following description regarding drug therapy: Atopic dermatitis is a polygenic disease with causes that include genetic predisposition. There is no drug therapy that can cure the disease, and, as such, it is the standard to provide symptomatic treatment.(Furue et al., 2009: 1521)
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study
Published in Expert Opinion on Investigational Drugs, 2023
Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, Min Kyu Park, Jun Gi Hwang, Min-Gul Kim, Hyewon Chung, JongLyul Ghim, Jae-Yong Chung, Josef S. Smolen, Gerd R. Burmester, SungHyun Kim, YunJu Bae, DaBee Jeon, JaeKyoung Yoo, GoEun Yang, JiHun Bae, Edward Keystone
TESAEs were experienced by two (1.4%) and one (0.7%) participants in the CT-P47 and EU-tocilizumab groups, respectively (Table 4). Those in the CT-P47 group were of grade 2 in intensity: one participant tested positive for COVID-19 and subsequently discontinued the study due to isolation at a treatment center. The participant received non-steroidal anti-inflammatory drugs and cough remedy and was later discharged. In the second case, a participant experienced pain in an extremity following a car accident. This participant received acupuncture and electrotherapy and completed the study. Both events were considered to be unrelated to study drug. The TESAE in the EU-tocilizumab group was a headache of grade 3 intensity. The participant was hospitalized and received symptomatic treatment with analgesics, tranquilizers, antidepressants, antiemetics, and antihypertensives. The event was considered possibly related to study drug and the participant completed the study. There were no TEAEs leading to discontinuation of the study drug or death (Table 4).
The protective effect of chrysin against oxidative stress and organ toxicity in rats exposed to propetamphos
Published in Drug and Chemical Toxicology, 2022
Muhammet Yasin Tekeli, Latife Çakır Bayram, Gökhan Eraslan, Zeynep Soyer Sarıca
While literature reports are available on the effects of propetamphos exposure on lipid peroxidation/oxidative stress (Kanbur et al. 2008, 2009, Eraslan et al. 2016) as well as on the effects of some flavonoids on lipid peroxidation/oxidative stress caused by propetamphos intoxication (Kanbur et al. 2009), to the authors’ knowledge, the potential effects of chrysin have not been studied before. Today there are several antidote treatment options used in cases of organophosphate insecticide intoxication (Kassa 2002, Cherian et al. 2005, Paudyal 2008, Chung and Keun Roh 2013, Muckova et al. 2019). Symptomatic treatment options are also available (Paudyal 2008, Chung and Keun Roh 2013, Eddleston and Chowdhury 2016). However, adverse effects may occur during the use of these antidotal agents (Barelli et al. 2011, Chacko and Peter 2019), and free radicals can be generated (Muckova et al. 2019). Therefore, this study was designed to determine whether it chrysin could be used as a supportive agent in treatment, both to mitigate the effects of free radicals generated due to propetamphos intoxication and to minimize the adverse effects of antidotes used to treat intoxication. For this purpose, some oxidative stress/lipid peroxidation/antioxidant status markers and biochemical parameters were investigated in some tissues/the blood of rats, and histopathological evaluations were made in the sampled tissues.
Pharmacotherapy for the management of the symptoms of Machado-Joseph Disease
Published in Expert Opinion on Pharmacotherapy, 2022
Jessica Blanc Leite Oliveira, Alberto R.M. Martinez, Marcondes Cavalcante França Jr
Currently, there are no disease-modifying therapies for SCA3/MJD. For this reason, symptomatic treatment is the mainstay of clinical care. Proper management of many symptoms may improve the overall functioning and quality of life of affected individuals. One should carefully evaluate every patient, looking for motor and non-motor manifestations. It is important to realize that ataxia is a universal feature in SCA3/MJD, but the associated manifestations vary from patient to patient. Dystonia and spasticity are more frequent in early-onset cases, whereas peripheral neuropathy is more often found in late-onset patients. So, the pharmacological management plan should be tailored for each individual. For specific SCA3/MJD-related manifestations, there is some information coming from controlled studies that may assist us in therapeutic choices. This is the case, for example, with ataxia, dystonia, and cramps [12–15,34,59,60]. However, for the remaining SCA3/MJD-related manifestations, pharmacological interventions are ultimately based on empirical evidence or experts’ opinion.